A recent paper identified a small-molecule agonist of GSDMD and showed that it could induce protective antitumour immunity in various cancer models by inducing pyroptosis in a small fraction of cancer cells, without causing apparent systemic toxicity (Fontana et al, 2024) (Fig. 4A, Table 1). Here, GSDMD is linked to cancer.